Jason Powell

Jason Powell, Pharm.D., BCACP

Clinical Assistant Professor

Department: Pharmacy Education and Practice
Business Phone: (352) 265-7015
Business Email: jpdrums@ufl.edu

About Jason Powell

Dr. Jason Powell, a Board Certified Ambulatory Care Pharmacist, is a proud native of Gainesville, FL, with deep connections to the community. From his youth, he was a regular at UF sporting events and a member of the drumline in the Pride of the Sunshine Gator Marching Band during his undergraduate years at the University of Florida (UF). After completing his Doctor of Pharmacy (Pharm.D.) at UF, Dr. Powell completed a residency at the UF College of Pharmacy, specializing in ambulatory care and academia. Since 2012, Dr. Powell has been an integral part of UF’s academic community, precepting pharmacy students during their ambulatory care rotations and teaching in the working professional PharmD program. His passion for education was recognized in 2013 when he was appointed Clinical Assistant Professor with the UF College of Pharmacy. In this role, he maintained a clinical practice site at UFHealth Family Medicine Eastside. Dr. Jason Powell has taught a variety of courses at the University of Florida College of Pharmacy, focusing on ambulatory care and patient-centered practices. His teaching contributions include professional skills lab courses where he helps develop students’ clinical competencies such as patient interviewing, taking vital signs, and use of several point of care lab devices. He also teaches within several patient care courses, fostering students’ clinical decision-making using both lectures and clinical cases adapted from his practice. As the co-coordinator of the ambulatory care elective, he even further immerses students within a patient simulation, solidifying the management of complex disease states. These courses highlight his commitment to preparing future pharmacists within a number of clinical settings and patient care needs. In addition to his extensive teaching and precepting experience, Dr. Powell actively practices as a clinical pharmacist at UF Health Family Medicine, focusing on management of many chronic disease states including anticoagulation management, diabetes, hypertension, and metabolic syndrome. Within the practice he focuses on providing primary care services while collaborating with an interprofessional team to improve patient outcomes. Dr. Powell is deeply committed to scholarly work, focusing on ambulatory care practice, newly approved medications, and clinical research. He has contributed to various publications and continues to advise Doctor of Pharmacy students while maintaining a robust clinical practice.

Accomplishments

Member
2009-Current · Kappa Psi Pharmaceutical Fraternity

Teaching Profile

Courses Taught
2018
PHA5165L Prof Skills Lab V
2018
PHA5763 Ambulatory Care Advanced Pharmacy Practice Experience
2018
PHA5781 Patient Care I
2018,2021-2023
PHA5876C Pt Care 8 Complex Pts
2015-2016
PHA5161L Pract Skills Lab I
2016,2024
PHA5878C Pt Care 3: Cv and Pulm
2013
PHA5108L Pharmaceu Skls Lab 1
2021-2025
PHA5166L Prof Skills Lab Vi
2021-2024
PHA5060 Ambulatory Care
2022-2024
PHA5788C Patient Care 6
2022-2023
PHA5163L Prac Skills Lab III
2023-2025
PHA5789C Patient Care 7
2024-2025
PHA5561 Pathphys-Pt Assess II
2024-2025
PHA5787C Pt Care 5: Endo

Board Certifications

  • Board certified ambulatory care pharmacist
    Board of Pharmacy Specialties

Research Profile

Dr. Powell’s research interests include hyperlipidemia medication, warfarin and diabetes care.

Publications

Academic Articles
2024
Partnering for Better Health: Using Continuous Glucose Monitoring and Clinical Pharmacist Collaboration to Improve Glycemic Control in Underserved Patients With Type 2 Diabetes.
Clinical therapeutics. 46(1):e7-e11 [DOI] 10.1016/j.clinthera.2023.10.005. [PMID] 38165024.
2024
Use of Dulaglutide, Semaglutide, and Tirzepatide in Diabetes and Weight Management.
Clinical therapeutics. 46(3):289-292 [DOI] 10.1016/j.clinthera.2023.12.014. [PMID] 38310052.
2021
Bempedoic Acid: A New Tool in the Battle Against Hyperlipidemia.
Clinical therapeutics. 43(2):410-420 [DOI] 10.1016/j.clinthera.2020.12.001.
2020
Brexanolone (Zulresso): Finally, an FDA-Approved Treatment for Postpartum Depression
Annals of Pharmacotherapy. 54(2):157-163 [DOI] 10.1177/1060028019873320.
2020
Emergency Authorization of Chloroquine and Hydroxychloroquine for Treatment of COVID-19.
The Annals of pharmacotherapy. 54(8):827-831 [DOI] 10.1177/1060028020925558.
2020
Oral Semaglutide: The First-available Noninjectable Glucagon-like Peptide 1 Receptor Agonist.
Clinical therapeutics. 42(10):2100-2116 [DOI] 10.1016/j.clinthera.2020.07.017.
2020
Solriamfetol for Excessive Sleepiness in Narcolepsy and Obstructive Sleep Apnea.
The Annals of pharmacotherapy. 54(10):1016-1020 [DOI] 10.1177/1060028020915537.
2019
Andexanet alfa: A Novel Factor Xa Inhibitor Reversal Agent.
The Annals of pharmacotherapy. 53(9):940-946 [DOI] 10.1177/1060028019835209. [PMID] 30813754.
2019
Ertugliflozin: A New Option in the SGLT-2 Inhibitor Market for the Treatment of Type 2 Diabetes Mellitus.
The Annals of pharmacotherapy. 53(5):478-485 [DOI] 10.1177/1060028018818829. [PMID] 30522346.
2016
Patient satisfaction with extended-interval warfarin monitoring.
Journal of thrombosis and thrombolysis. 42(4):486-93 [DOI] 10.1007/s11239-016-1385-9. [PMID] 27251646.
2015
Feasibility of Extended-interval Follow-up for Patients Receiving Warfarin.
Cardiovascular therapeutics. 33(3):98-103 [DOI] 10.1111/1755-5922.12115. [PMID] 25786578.
2015
Sodium-glucose cotransporter 2 inhibitors: the new option for diabetes mellitus management.
Southern medical journal. 108(2):82-90 [DOI] 10.14423/SMJ.0000000000000233. [PMID] 25688892.
2014
Optimal management of type 2 diabetes in patients with increased risk of hypoglycemia.
Diabetes, metabolic syndrome and obesity : targets and therapy. 7:85-94 [DOI] 10.2147/DMSO.S48896. [PMID] 24623984.
2013
Canagliflozin: a novel treatment option for type 2 diabetes.
Drug design, development and therapy. 7:1399-408 [DOI] 10.2147/DDDT.S48937. [PMID] 24285921.
2013
Lorcaserin for weight management.
Diabetes, metabolic syndrome and obesity : targets and therapy. 6:209-16 [DOI] 10.2147/DMSO.S36276. [PMID] 23788837.
2013
New and emerging pharmacologic therapies for type 2 diabetes, dyslipidemia, and obesity.
Clinical therapeutics. 35(1):A3-17 [DOI] 10.1016/j.clinthera.2012.12.012. [PMID] 23328274.

Education

Pharm.D.
2012 · University of Florida

Contact Details

Phones:
Business:
(352) 265-7015
Emails:
Business:
jpdrums@ufl.edu
Addresses:
Business Mailing:
PO BOX 100486
PHARMACOTHERAPY & TRANSLATIONAL RESEARCH
GAINESVILLE FL 326100486